Company intelligence / Profile preview

Black Swan Group

Wake Forest, North Carolina, United Statesblackswanltd.com ↗

Ownership: Private
Development stage: Commercial

Overview

Black Swan Pharmaceuticals develops gene-targeted antisense oligonucleotide therapies for neurodegenerative diseases such as ALS/MND and Parkinson’s. The company has filed at least one patent application related to SOD1-associated disease treatment. It operates in partnership with academic institutions like the Perron Institute to accelerate preclinical research toward clinical readiness, focusing on rapid translation from laboratory findings to potential patient treatments. No clinical data or trial outcomes have been published.

Therapeutic areas: Neurology
Modalities: Antisense oligonucleotide (antisense RNA-based therapeutics)Gene therapy (gene targeting therapeutics)
Industry: Biotech

Partnerships

Perron Institute for Translational and Clinical Research [Western Australia]

Beyond the preview

Go deeper on Black Swan Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Black Swan Group.

Explore the full profile